Skip to content

ImmunoModulation effects of early therapeutic NORMothermia in febrile severe Septic patients

Immunomodulation effects of early therapeutic normothermia in febrile severe septic patients

Status
Active, not recruiting
Phases
Phase 2Phase 3
Study type
Interventional
Source
TCTR
Registry ID
TCTR20160321001
Enrollment
Unknown
Registered
2016-03-21
Start date
2016-05-16
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sepsis sepsis therapeutic normothermia fever control immunomodulation neutrophil chemotaxis cytokines CD11b mHLA&#45

Interventions

Therapeutic normothermia with goal of body temperature 36&#45
degree Celsius for 24 hours&#44
using active external physical cooling device ,Standard treatment of fever using acetaminophen when body temperature more than 39.5&#45
degree Celsius
Experimental Other,Active Comparator Other
Therapeutic normothermia,Standard treatment

Sponsors

Faculty of Medicine, Chulalongkorn University
Lead Sponsor
Faculty of Medicine&#44
Collaborator
Chulalongkorn University
Collaborator

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Diagnosis of severe sepsis by the definition of Surviving Sepsis Campaign Guideline 2012 2. Body temperature more than 38.3 degree-Celsius 3. Serum lactate > 4mmol/L or systolic blood pressure less than 90 mmHg after 1 litres of intravenous fluid or need vasopressor to maintain systolic blood pressure more than 90 mmHg

Exclusion criteria

Exclusion criteria: 1. expected to be deceased within 24 hours 2. Terminally ill patients that do not want to be resuscitated 3. Causative organism suspected to be from other organisms other than bacteria 4. Pregnant patients 5. Immunocompromised such as HIV, post-splecnectomy, neutropenia, on immunosupressive agent 6. Transferred from other hospitals 7. Diagnosis of severe sepsis more than 12 hours 8. Patients with acute brain injury

Design outcomes

Primary

MeasureTime frame
feasibility 0-24 hours more than 80% of the time point during intervention that the temperature could be controlled under 3

Secondary

MeasureTime frame
mortality rate 14 and 28 day mortality rate,organ dysfunction 7&#44; 14 and 28 day SOFA score,lactate clearance 1&#44; 7 day lactate,mechanical ventilation free day during admission day without mechanical ventilation,duration of vasopressor use during admission duration of vasopressor use : hours ,temperature difference between groups 0&#45;24 hours temperature ,immunomodulation effect 0&#44;24&#44;72 hours neutrophil chemotaxis&#44; mHLA&#45;DR&#44; CD11b&#44; IL&#45;6&#44; IL&#45;10&#44; CRP,hospital length of stay during admission length of stay,major bleeding during admission major bleeding criteria,secondary infection during admission secondary infection,shivering 0&#45;24 hours shivering score,new arrhythmia 0&#45;24 hours incidence,intractable hyperglycemia 0&#45;24 hours incidence,hypothermia < 36 C 0&#45;24 hours incidence

Contacts

Public ContactJutamas Saoraya

Department of Emergency Medicine&#44; Faculty of Medicine&#44; Chulalaongkorn University

jsaoraya@gmail.com+66897632763

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026